Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck returning S1P receptor agonist to Ono

Merck KGaA (Xetra:MRK) is returning rights to Ono Pharmaceutical Co. Ltd.

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE